Mechanism of glioma stem cells with high expression of PTPRZ1 inducing TAMs polarization to M2 immunosuppressive phenotype
Basic Medicine|更新时间:2026-01-09
|
Mechanism of glioma stem cells with high expression of PTPRZ1 inducing TAMs polarization to M2 immunosuppressive phenotype
Journal of Army Medical UniversityVol. 46, Issue 8, Pages: 796-803(2024)
作者机构:
1.400038 重庆,陆军军医大学(第三军医大学)第一附属医院:病理科
2.400039 重庆,金凤实验室,渝粤病理科学研究中心
3.400038 重庆,陆军军医大学(第三军医大学)第一附属医院:输血科
4.400038 重庆,陆军军医大学(第三军医大学)第一附属医院:神经外科
作者简介:
基金信息:
the Project for Young Scientists of National Key Research and Development Program of China(2021YFA1103000);the General Program of National Natureal Science Foundation of China(82373191);the National Nature Science Foundation for Young Scholars of China(82102889);the Postdoctoral Science Foundation of Chongqing Natural Science Foundation(cstc2021jcyj-bshX0063)
Lele AN, Ying YANG, Qing LIU, et al. Mechanism of glioma stem cells with high expression of PTPRZ1 inducing TAMs polarization to M2 immunosuppressive phenotype[J]. Journal of Army Medical University, 2024, 46(8): 796-803.
DOI:
Lele AN, Ying YANG, Qing LIU, et al. Mechanism of glioma stem cells with high expression of PTPRZ1 inducing TAMs polarization to M2 immunosuppressive phenotype[J]. Journal of Army Medical University, 2024, 46(8): 796-803. DOI: 10.16016/j.2097-0927.202401021.
Mechanism of glioma stem cells with high expression of PTPRZ1 inducing TAMs polarization to M2 immunosuppressive phenotype
GEO)中配对GSCs和NSTCs转录组测序数据(GSE54791)中获得差异表达基因;于癌症和肿瘤基因图谱(the cancer genome atlas,TCGA)数据库GBM队列中鉴定预后不良基因集。上述基因集与编码人膜蛋白基因集取交集获得PTRRZ1,利用基因集富集分析(gene set enrichment Analysis,GSEA)比较TCGA数据库中高表达和低表达PTPRZ1的GBM样本的差异通路。利用转录组测序鉴定PTPRZ1-Ctrl GSCs和PTPRZ1-KO GSCs组中差异表达基因并通过RT-qPCR和Western blot验证。
To explore the effect of glioma stem cells with high expression of protein tyrosin phosphatase receptor type Z1 (PTPRZ1)on the phenotypic polarization and phagocytosis of tumor-associated macrophages and its regulatory mechanism.
Methods
2
GSCs and non-stem tumor cells (NSTCs) were screened out from human glioblastoma (GBM) specimens using flow cytometry
and the PTPRZ1 expression in paired GSCs and NSTCs were detected. Human peripheral blood mononuclear cells (PBMC)-derived CD14
+
monocytes were exposed to the conditioned medium from glioma cells or recombinant chemokine C-C motif ligand 20 (CCL20) for TAM polarization. Stable PTPRZ1 knockout GSCs (PTPRZ1-KO GSCs) were constructed using CRISPR/Cas9. TAM phagocytosis to GSCs
NSTCs
PTPRZ1-Control GSCs (PTPRZ1-Ctrl GSCs) and PTPRZ1-KO GSCs and the expression of immunosuppressive phenotype (M2) polarization marker CD163 were examined using flow cytometry. Differentially expressed genes (DEGs) between paired GSCs and NSTCs were dete
rmined using a bulk RNA-sequencing dataset (GSE54791) from Gene Expression Omnibus (GEO). A gene set informing worse outcome of patients with GBM was generated using The Cancer Genome Atlas (TCGA)-GBM cohort. By intersecting the aforementioned gene set with the gene set that encodes for human membrance proteins
the PTPRZ1 gene is obtained. Gene set enrichment analysis (GSEA) was used for pathway enrichment analysis to compare the differentially regulated pathways between GBMs with high or low PTPRZ1 expression. Bulk RNA sequencing
qRT-PCR and Western blotting were used to identify the DEGs between PTPRZ1-KO GSCs and PTPRZ1-Ctrl GSCs.
Results
2
GSCs were more capable of escaping from TAM phagocytosis than NSTCs (
P
<
0.05) and had specifically up-regulated PTPRZ1 expression. PTPRZ1-KO significantly suppressed GSCs escaping from TAM phagocytosis (
P
<
0.01). GBMs with high PTPRZ1 expression showed significant inhibition of pathways mediating phagocytosis (
P
<
0.05). The expression of CCL20 as a M2 TAM polarization chemokine was significantly down-regulated in PTPRZ1-KO GSCs (
P
<
0.05). Treatment with recombinant CCL20 up-regulated the expression of CD163 as a M2 TAM marker in TAM.
Conclusion
2
PTPRZ1
+
GSCs mediate M2 TAM polarization and inhibit TAM phagocytosis
which may be related to the up-regulation of CCL20 in PTPRZ1
+
GSCs.
关键词
Keywords
references
TAN A C, ASHLEY D M, LÓPEZ G Y, et al . Management of glioblastoma: state of the art and future directions[J ] . CA Cancer J Clin, 2020, 70(4): 299-312. DOI: 10.3322/caac.21613.
LUO J Y, YANG J, LI X, et al . Brain targeting of 2-deoxyglucose modified lipid nanoparticles co-loaded with siPD-L1 and temozolomide[J ] . J Air Force Med Univ, 2024, 45(1): 73-79. DOI: 10.13276/j.issn.2097-1656.2024.01.015.
GISINA A, KHOLODENKO I, KIM Y, et al . Glioma stem cells: novel data obtained by single-cell sequencing[J ] . Int J Mol Sci, 2022, 23(22): 14224. DOI: 10.3390/ijms232214224.
BOYD N H, TRAN A N, BERNSTOCK J D, et al . Glioma stem cells and their roles within the hypoxic tumor microenvironment[J ] . Theranostics, 2021, 11(2): 665-683. DOI: 10.7150/thno.41692.
SHI Y, PING Y F, ZHOU W C, et al . Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth[J ] . Nat Commun, 2017, 8: 15080. DOI: 10.1038/ncomms15080.
YIN W, PING Y F, LI F, et al . A map of the spatial distribution and tumour-associated macrophage states in glioblastoma and grade 4 IDH-mutant astrocytoma[J ] . J Pathol, 2022, 258(2): 121-135. DOI: 10.1002/path.5984.
LIU Q, YANG Y, AN L L, et al . Inhibiting and invasive self-renewal effect of PTPRZ1 monoclonal antibody on glioma stem cells[J ] . J Army Medical University, 2023, 45(24): 2530-2536. DOI: 10.16016/j.2097-0927.202308042.
GANGOSO E, SOUTHGATE B, BRADLEY L, et al . Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion[J ] . Cell, 2021, 184(9): 2454-2470.e26. DOI: 10.1016/j.cell.2021.03.023.
GROVER A, SANSEVIERO E, TIMOSENKO E, et al . Myeloid-derived suppressor cells: a propitious road to clinic[J ] . Cancer Discov, 2021, 11(11): 2693-2706. DOI: 10.1158/2159-8290.CD-21-0764.
WANG G Q, ZHONG K H, WANG Z, et al . Tumor-associated microglia and macrophages in glioblastoma: from basic insights to therapeutic opportunities[J ] . Front Immunol, 2022, 13: 964898. DOI: 10.3389/fimmu.2022.964898.
ZHOU W C, KE S Q, HUANG Z, et al . Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth[J ] . Nat Cell Biol, 2015, 17(2): 170-182. DOI: 10.1038/ncb3090.
TAO W W, CHU C W, ZHOU W C, et al . Dual role of WISP1 in maintaining glioma stem cells and tumor-supportive macrophages in glioblastoma[J ] . Nat Commun, 2020, 11(1): 3015. DOI: 10.1038/s41467-020-16827-z.
HIPPE A, BRAUN S A, OLÁH P, et al . EGFR/Ras-induced CCL20 production modulates the tumour microenvironment[J ] . Br J Cancer, 2020, 123(6): 942-954. DOI: 10.1038/s41416-020-0943-2.
KADOMOTO S, IZUMI K, MIZOKAMI A. The CCL20-CCR6 axis in cancer progression[J]. Int J Mol Sci, 2020, 21(15): 5186. DOI: 10.3390/ijms21155186.
WANG D, YANG L, YU W N, et al . Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling[J ] . J Immunother Cancer, 2019, 7(1): 215. DOI: 10.1186/s40425-019-0701-2.
XU C C, FAN L N, LIN Y F, et al . Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization[J ] . Gut Microbes, 2021, 13(1): 1980347. DOI: 10.1080/19490976.2021.1980347..
DONG D D, ZHANG G J, YANG J C, et al . The role of iron metabolism in cancer therapy focusing on tumor-associated macrophages[J ] . J Cell Physiol, 2019, 234(6): 8028-8039. DOI: 10.1002/jcp.27569.
OVAIS M, GUO M Y, CHEN C Y. Tailoring nanomaterials for targeting tumor-associated macrophages[J]. Adv Mater, 2019, 31(19): e1808303. DOI: 10.1002/adma.201808303.
VAN VLERKEN-YSLA L E, RIOS-DORIA J, MOYNIHAN J, et al . Abstract 4779: targeting the CCL20-CCR6 axis as a novel opportunity to stimulataneously modulate cancer stem cells and the tumor-immune infiltrate by a dual anti-cancer mechanism[J ] . Cancer Res, 2017, 77(13_Supplement): 4779. DOI: 10.1158/1538-7445.am2017-4779.
ZHENG W J, ZHANG H, HUO Y, et al . Application of macrophage phagocytic checkpoint blockade in anti-tumor immunotherapy[J ] . J Air Force Med Univ, [2024-03-05 ] . http://kns.cnki.net/kcms/detail/61.1526.R.20240129.1508.004.html http://kns.cnki.net/kcms/detail/61.1526.R.20240129.1508.004.html ..